Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20327-20344

  Ali, Naushad ^a,b   Chandrakesan, Parthasarathy ^a   Nguyen, Charles B ^a   Husain, Sanam ^a,b   Gillaspy, Allison F ^a,b   Huycke, Mark ^b   Berry, William L ^a   May, Randal ^a   Qu, Dongfeng ^a   Weygant, Nathaniel ^a   Sureban, Sripathi M ^a,b   Bronze, Michael S ^a   Dhanasekaran, Danny N ^a,b   Houchen, Courtney W ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c NONE   (United States)

Author keywords

Cancer stem cell; DCLK1; HCV; Hepatocellular carcinoma; Inflammation

Indexed keywords

BRM PROTEIN; CALGRANULIN B; DOUBLECORTIN LIKE KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MYC PROTEIN; PHOSPHOTRANSFERASE; RIBAVIRIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; DCLK1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL MIGRATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; EMBRYO; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; GENETICS; INFLAMMATION; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84940192078     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3972     Document Type: Article

References (58)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273 e1261.
2. Yang JD and Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology & hepatology. 2010; 7:448-458.
3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. International journal of cancer Journal international du cancer. 2006; 118:3030-3044.
4. Poenisch M and Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2010; 30:333-347.
5. Lindenbach BD and Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005; 436:933-938.
6. Ryder SD. Outcome of hepatitis C infection: bleak or benign? J Hepatol. 2007; 47:4-6.
7. Qu L and Lemon SM. Hepatitis a and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin Liver Dis. 2010; 30:319-332.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-249.
9. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England journal of medicine. 2014; 370:1483-1493.
10. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England journal of medicine. 2014; 370:1889-1898.
11. Hagan LM, Yang Z, Ehteshami M and Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. Journal of viral hepatitis. 2013; 20:847-857.
12. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L and Reddy EP. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009; 49:318-329.
13. Lobo NA, Shimono Y, Qian D and Clarke MF. The biology of cancer stem cells. Annual review of cell and developmental biology. 2007; 23:675-699.
14. Frank NY, Schatton T and Frank MH. The therapeutic promise of the cancer stem cell concept. The Journal of clinical investigation. 2010; 120:41-50.
15. Yamashita T and Wang XW. Cancer stem cells in the development of liver cancer. The Journal of clinical investigation. 2013; 123:1911-1918.
16. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S and Houchen CW. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol. 2011; 85:12292-12303.
17. Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP and Houchen CW. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011; 9:40.
18. May R, Sureban SM, Hoang N, Riehl TE, Lightfoot SA, Ramanujam R, Wyche JH, Anant S and Houchen CW. Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells. 2009; 27:2571-2579.
19. Gagliardi G, Goswami M, Passera R and Bellows CF. DCLK1 immunoreactivity in colorectal neoplasia. Clinical and experimental gastroenterology. 2012; 5:35-42.
20. May R, Riehl TE, Hunt C, Sureban SM, Anant S and Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells. 2008; 26:630-637.
21. Westphalen CB, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, Brandtner A, Setlik W, Remotti H, Muley A, Chen X, May R, Houchen CW, Fox JG, Gershon MD, Quante M, et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. The Journal of clinical investigation. 2014; 124:1283-1295.
22. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, Isomura A, Kawada K, Sakai Y, Yanagita M, Kageyama R, Kawaguchi Y, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature genetics. 2012; 45:98-103.
23. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K and Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007; 46:48-57.
24. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH and Gale M, Jr. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS pathogens. 2013; 9:e1003330.
25. Burdette D, Haskett A, Presser L, McRae S, Iqbal J and Waris G. Hepatitis C virus activates interleukin-1beta via caspase-1-inflammasome complex. The Journal of general virology. 2012; 93:235-246.
26. Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P and Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 2009; 50:1251-1262.
27. Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C and Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. Journal of molecular biology. 2006; 359:961-972.
28. Gebhardt C, Nemeth J, Angel P and Hess J. S100A8 and S100A9 in inflammation and cancer. Biochemical pharmacology. 2006; 72:1622-1631.
29. Wu R, Duan L, Ye L, Wang H, Yang X, Zhang Y, Chen X, Zhang Y, Weng Y, Luo J, Tang M, Shi Q, He T and Zhou L. S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway. International journal of oncology. 2013; 42:1001-1010.
30. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wikstrom P, Bergh A, Roth J, Ivars F and Leanderson T. S100A9 interaction with TLR4 promotes tumor growth. PloS one. 2012; 7:e34207.
31. Vogl T, Gharibyan AL and Morozova-Roche LA. Pro-Inflammatory S100A8 and S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes. International journal of molecular sciences. 2012; 13:2893-2917.
32. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D and Tessier PA. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1.). PloS one. 2013; 8:e72138.
33. Lin PT, Gleeson JG, Corbo JC, Flanagan L and Walsh CA. DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J Neurosci. 2000; 20:9152-9161.
34. Kim MH, Cierpicki T, Derewenda U, Krowarsch D, Feng Y, Devedjiev Y, Dauter Z, Walsh CA, Otlewski J, Bushweller JH and Derewenda ZS. The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nature structural biology. 2003; 10:324-333.
35. Guo JT, Bichko VV and Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001; 75:8516-8523.
36. Ali N, Tardif KD and Siddiqui A. Cell-free replication of the hepatitis C virus subgenomic replicon. J Virol. 2002; 76:12001-12007.
37. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR and Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008; 134:812-822.
38. Dijkmans TF, van Hooijdonk LW, Fitzsimons CP and Vreugdenhil E. The doublecortin gene family and disorders of neuronal structure. Central nervous system agents in medicinal chemistry. 2010; 10:32-46.
39. Deisboeck TS and Couzin ID. Collective behavior in cancer cell populations. BioEssays: news and reviews in molecular, cellular and developmental biology. 2009; 31:190-197.
40. Deuel TA, Liu JS, Corbo JC, Yoo SY, Rorke-Adams LB and Walsh CA. Genetic interactions between doublecortin and doublecortin-like kinase in neuronal migration and axon outgrowth. Neuron. 2006; 49:41-53.
41. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG and Houchen CW. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PloS one. 2013; 8:e73940.
42. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, Werner S, Sorg C and Roth J. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004; 104:4260-4268.
43. Kwon CH, Moon HJ, Park HJ, Choi JH and Park do Y. S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-kappaB activation in gastric cancer cells. Molecules and cells. 2013; 35:226-234.
44. Ali N, Allam H, Bader T, May R, Basalingappa KM, Berry WL, Chandrakesan P, Qu D, Weygant N, Bronze MS, Umar S, Janknecht R, Sureban SM, Huycke M and Houchen CW. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PloS one. 2013; 8:e80304.
45. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, Pikarsky E and Stanger BZ. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell stem cell. 2014; 15:340-349.
46. Hermani A, De Servi B, Medunjanin S, Tessier PA and Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Experimental cell research. 2006; 312:184-197.
47. Markowitz J and Carson WE, 3rd. Review of S100A9 biology and its role in cancer. Biochimica et biophysica acta. 2013; 1835:100-109.
48. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, Nordle O, Forsberg G, Carducci MA and Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:4022-4028.
49. Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D and Nefedova Y. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. Journal of immunology. 2013; 190:3815-3823.
50. Chen H, Xu C, Jin Q and Liu Z. S100 protein family in human cancer. American journal of cancer research. 2014; 4:89-115.
51. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, Carithers RL, Jr., Wood BL, Perkins JD and Gretch DR. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology. 2006; 130:1107-1116.
52. Wilson BG and Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nature reviews Cancer. 2011; 11:481-492.
53. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC and Roberts CW. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Molecular and cellular biology. 2014; 34:1136-1144.
54. Rodriguez-Nieto S, Canada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, Sanchez-Verde L, Pisano DG and Sanchez-Cespedes M. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Human mutation. 2011; 32:E1999-2017.
55. Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W, Jr., Murchardt C, Yaniv M, Sherman LS, Knudsen ES and Weissman BE. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 2002; 21:1196-1207.
56. Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S and Houchen CW. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014; 5:9269-9280.
57. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI, Rebres R, Roach T, Seaman W, Simon MI and Fraser ID. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci U S A. 2006; 103:13759-13764.
58. Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S and Houchen CW. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology. 2009; 137:649-659, 659 e641-642.